CVE-2017-0016

Description

Microsoft Windows 10 Gold, 1511, and 1607; Windows 8.1; Windows RT 8.1; Windows Server 2012 R2, and Windows Server 2016 do not properly handle certain requests in SMBv2 and SMBv3 packets, which allows remote attackers to execute arbitrary code via a crafted SMBv2 or SMBv3 packet to the Server service, aka "SMBv2/SMBv3 Null Dereference Denial of Service Vulnerability."

Category

5.9
CVSS
Severity: Medium
CVSS 3.0 •
CVSS 2.0 •
EPSS 49.20% Top 5%
Vendor Advisory microsoft.com
Affected: Microsoft Corporation SMBv2/SMBv3
Published at:
Updated at:

References

Link Tags
http://www.securityfocus.com/bid/95969 third party advisory vdb entry
https://portal.msrc.microsoft.com/en-US/security-guidance/advisory/CVE-2017-0016 patch vendor advisory
http://www.securitytracker.com/id/1037767 vdb entry
http://www.securitytracker.com/id/1038001 vdb entry

Frequently Asked Questions

What is the severity of CVE-2017-0016?
CVE-2017-0016 has been scored as a medium severity vulnerability.
How to fix CVE-2017-0016?
To fix CVE-2017-0016, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2017-0016 being actively exploited in the wild?
It is possible that CVE-2017-0016 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~49% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2017-0016?
CVE-2017-0016 affects Microsoft Corporation SMBv2/SMBv3.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.